Arcturus Therapeutics

Yahoo Finance • 21 days ago

Arcturus outlines 12-week cystic fibrosis study launch in 2026 amid cost controls and delayed KOSTAIVE BLA

Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 MANAGEMENT VIEW * CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic fibrosis (CF), showed "... Full story

Yahoo Finance • last month

Arcturus cut to Neutral at Citi on data for mRNA candidate

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Arcturus Therapeutics (NASDAQ:ARCT [https://seekingalpha.com/symbol/ARCT]) traded lower on Friday after Citi downgraded the San Diego, California-based biotech, citing m... Full story

Yahoo Finance • last month

Coinbase, eBay upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Citizens JMP upgraded eBay (EBAY) to O... Full story

Yahoo Finance • last month

Trending tickers: Tesla, IonQ, IBM, Arcturus and Unilever

Tesla (TSLA) Tesla reported a rebound in quarterly revenue overnight, marking the end of two consecutive periods of decline. However, profits fell sharply as higher costs and lower vehicle prices weighed on the results. The weaker-than-ex... Full story

Yahoo Finance • 2 months ago

Noteworthy Thursday Option Activity: AKRO, DHI, AFRM

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Akero Therapeutics Inc (Symbol: AKRO), where a total of 8,313 contracts have traded so far, representing approximately 831,300 und... Full story

Yahoo Finance • 2 months ago

Cathie Wood's Ark Invest weekly recap: adds Chinese tech names, Intellia Therapeutics

ARK Invest CEO Cathie Wood recently pointed out that the AI space is ruled by “big four” players: OpenAI, Anthropic, Elon Musk’s xAI, and Google’s (GOOG [https://seekingalpha.com/symbol/GOOG]) Gemini, describing the competition among these... Full story

Yahoo Finance • 4 months ago

Meta, Goldman Sachs lead Tuesday's market cap stock movers

Tuesday’s market has seen notable shifts with several stocks making significant intra-day movements. Mega-cap stocks like Facebook Inc (NASDAQ:META) and Goldman Sachs Group (NYSE:GS) are experiencing upward trends, while large-cap stoc... Full story

Yahoo Finance • 4 months ago

Top movers in Tuesday's session

Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT... Full story

Yahoo Finance • 4 months ago

Wells Fargo lowers Arcturus Therapeutics stock price target to $42 on model updates

Investing.com - Wells Fargo lowered its price target on Arcturus Therapeutics (NASDAQ:ARCT) to $42.00 from $45.00 on Tuesday while maintaining an Overweight rating on the stock. The biotech company, currently valued at $309 million, has sh... Full story

Yahoo Finance • 4 months ago

Arcturus outlines pivotal trial plans and advances CF and OTC programs with regulatory meetings expected in 2026

Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 MANAGEMENT VIEW * CEO Joseph E. Payne reported that the ARCT-032 program for Cystic Fibrosis (CF) has completed enrollment and dosing for the 5-milligram cohort... Full story

Yahoo Finance • 4 months ago

Arcturus Therapeutics Holdings Inc earnings missed by $3.55, revenue fell short of estimates

Investing.com - Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) reported second quarter EPS of $-0.34, $3.55 worse than the analyst estimate of $3.21. Revenue for the quarter came in at $28.3M versus the consensus estimate of $191.77M.... Full story

Yahoo Finance • 4 months ago

Arcturus Therapeutics Q2 2025 Earnings Preview

* Arcturus Therapeutics (NASDAQ:ARCT [https://seekingalpha.com/symbol/ARCT]) is scheduled to announce Q2 earnings results on Monday, August 11th, after market close. * The consensus EPS Estimate is -$0.87 [https://seekingalpha.com/symb... Full story

Yahoo Finance • 4 months ago

Barrick Gold, Roivant Sciences, Owens & Minor to report earnings Monday

Earnings season continues, with several notable companies set to release their financial results for the upcoming trading day. Leading the pack are mining giant Barrick Gold, biopharmaceutical company Roivant Sciences (NASDAQ:ROIV), and he... Full story

Yahoo Finance • 5 months ago

Arcturus reports positive phase 2 results for OTC deficiency therapy

SAN DIEGO - Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a $375 million market cap biotech company whose stock has seen a -21% return year-to-date, announced positive interim results from Phase 2 trials of ARCT-810, an mRNA therapeut... Full story

Yahoo Finance • last year

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT-154,... Full story

Yahoo Finance • 2 years ago

18 High Growth Low PE Stocks

In this article, we will take a detailed look at the18 High Growth Low PE Stocks. For a quick overview of such stocks, read our article 5 High Growth Low PE Stocks. When value stocks came back with a vengeance in 2022, value investors che... Full story

Yahoo Finance • 2 years ago

12 Best Healthcare Stocks For the Long-Term

In this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview of the healthcare industry, then you can take a look at 5 Best Healthcare Stocks For the Long-Term. The healthcare ind... Full story

Yahoo Finance • 2 years ago

Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress

Expected cash runway extended to the end of 2026 $35 million milestone achieved under CSL collaboration ARCT-154 remains on track for Japan-NDA approval in December Enrollment target reached in Phase 3 bivalent COVID vaccine comparison... Full story

Yahoo Finance • 2 years ago

Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19

EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was met An additional Phase 3 booster study demonstrating non-inferiority of immune response compared to Comirnaty® and superiority of... Full story

Yahoo Finance • 3 years ago

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

KING OF PRUSSIA, Pa., Nov. 1, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arctur... Full story